Progressive EQUITY RESEARCH

TERN PLC SOFTWARE AND COMPUTER SERVICES

26 October 2021

TERN.L

21.5p

Market Cap: £75.6m



Source: LSE Data

KEY DATA	
Net (Debt)/Cash	£0.4m <i>(at 30/06/21)</i>
Enterprise value	£75.2m
Index/market	AIM
Next news	Full Year, March '22
Shares in Issue (m)	351.6
Chairman	Ian Ritchie
Chief Executive	Albert E Sisto
Finance Director	Sarah Payne

COMPANY DESCRIPTION

Tern predominantly invests in software companies, with proven technology, based in the UK but with global ambition.

www.ternplc.com

TERN PLC IS A RESEARCH CLIENT OF PROGRESSIVE

ANALYSTS

Gareth Evans

+44 (0) 20 7781 5301

+44 (0) 20 7781 5303

gevans@progressive-research.com

Tessa Starmer



tstarmer@progressive-research.com

Portfolio update – further positive news

Tern has announced an update on its portfolio of investee companies, following the August release that accompanied the FundamentalVR fundraise. Given the relatively short time between these updates, most of the news is operational from the various investees, each of which appears to be making good progress.

- Device Authority is growing its indirect channel, adding distribution deals with Trusted Objects and Titan Automotive. The business also hosted a well-attended (1,200+ registration) sector event, with Microsoft's active involvement. Importantly, the conference saw the launch of DA's new 'Edge' version of KeyScaler, a light version of the product delivering identity management in situations without a permanent internet connection but still offering the compliance and security elements that organisations require.
- FundamentalVR points to good ongoing win rates and order levels, with a "significant" win replacing a competitor product (difficult to achieve in such a regulated and managed environment as healthcare technology). Some 60% of revenues in recent months have been from new customers, with the other 40% being repeat purchases from the installed base.
- Wyld Networks is still seeing the benefits of its own IPO, successfully completed in July (on NASDAQ First North Growth Market, Stockholm). The business has published international patent applications for the first time, and is seeing ongoing purchase orders and building partnerships.
- InVMA points to the arrival of a new Head of Product within its USA operation, and is seeing strong sales growth for the core AssetMinder software platform, used in industrial and other settings.
- Talking Medicines remains the newest member of the portfolio, and highlights some recent market research suggesting that "social listening" (the area in which Talking Medicines is active) is in the five-year development plans of some 82% of pharma executives, with over twothirds of those not having chosen a provider.

Overall, this set of updates suggests that the portfolio businesses are concentrating on operational delivery, seeing success in their different sales strategies, and remain confident to invest and drive further growth, which in turn should generate shareholder value over time. We look forward to further updates in due course.

INVESTEE COMPANIES



This publication should not be seen as an inducement under MiFID II regulations. Please refer to important disclosures at the end of the document.

Disclaimers and Disclosures

Copyright 2021 Progressive Equity Research Limited ("PERL"). All rights reserved. Progressive's research is commissioned by the subject company under contract and is freely available to the public and all institutional investors. Progressive does not offer investors the ability to trade securities. Our publications should not, therefore, be considered an inducement under MiFID II regulations. PERL provides professional equity research services, and the companies researched pay a fee in order for this research to be made available. This report has been commissioned by the subject company and prepared and issued by PERL for publication in the United Kingdom only. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable; however, PERL does not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of PERL at the time of publication, and any estimates are those of PERL and not of the companies concerned unless specifically sourced otherwise. PERL is authorised and regulated by the Financial Conduct Authority (FCA) of the United Kingdom (registration number 697355).

This document is provided for information purposes only, and is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. Investors should seek advice from an Independent Financial Adviser or regulated stockbroker before making any investment decisions. PERL does not make investment recommendations. Any valuation given in a research note is the theoretical result of a study of a range of possible outcomes, and not a forecast of a likely share price. PERL does not undertake to provide updates to any opinions or views expressed in this document.

This document has not been approved for the purposes of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. It is not subject to any prohibition on dealing ahead of the dissemination of investment research.

PERL does not hold any positions in the securities mentioned in this report. However, PERL's directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. PERL or its affiliates may perform services or solicit business from any of the companies mentioned in this report.

The value of securities mentioned in this report can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of the shares mentioned in this report may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. It may be difficult to obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance.



Breadth of coverage

Analyst calibre



To arrange a meeting with the management team, or for further information about Progressive, please contact: Emily Ritchie +44 (0) 20 7781 5311 eritchie@progressive-research.com